ProstaVive
Prostate-support product guide
View Product
What qualifies as an NAD-support supplement on MenPS?
An NAD-support product must currently be positioned around NAD metabolism or contain a clearly identified NAD-related precursor such as nicotinamide riboside. The directory is product- and formula-focused. Inclusion does not mean the finished supplement has been independently shown to slow ageing or improve a clinical outcome.
The current verified snapshot includes several nicotinamide riboside products, including Tru Niagen 300 mg, Life Extension NAD+ Cell Regenerator, Thorne NiaCel 400, Renue By Science LIPO NR and DoNotAge Pure NR. These products are similar enough to compare directly but still differ in dose, serving format and formulation approach.
The current verified set is dominated by nicotinamide riboside
Tru Niagen 300 mg provides 300 mg of Niagen nicotinamide riboside chloride per vegetarian capsule. Life Extension NAD+ Cell Regenerator also provides 300 mg of NIAGEN nicotinamide riboside chloride per capsule. Renue By Science LIPO NR is a liposomal nicotinamide riboside product sold in a one-capsule serving format. DoNotAge Pure NR currently states 350 mg of nicotinamide riboside per capsule and a recommended daily serving of 700 mg.
This creates the first NAD-specific information-gain element: the page can compare products within the same broad precursor family rather than treating all longevity supplements as one class.
Dose and serving format create the clearest product differences
Current official product records show materially different per-capsule or daily-use presentations. Tru Niagen 300 mg and Life Extension NAD+ Cell Regenerator both provide 300 mg per capsule. DoNotAge Pure NR states 350 mg per capsule and 700 mg as its recommended daily serving. Renue By Science LIPO NR uses a liposomal delivery format. Thorne continues to market NiaCel 400 within its healthy-ageing range, but the exact current amount should be rechecked at the point of publication because surfaced Thorne pages have shown closely related representations around 400 mg versus 415 mg.
That means a useful NAD comparison should record both the precursor identity and the actual full serving, rather than compare brand names alone.
Single-ingredient and delivery-format differences matter
Tru Niagen 300 mg is a straightforward NR capsule. Life Extension NAD+ Cell Regenerator is also centered on NIAGEN NR in a capsule format. Renue By Science differentiates LIPO NR through liposomal delivery. DoNotAge Pure NR is positioned as a high-dose NR product with a two-capsule daily serving recommendation.
These are catalog distinctions. MenPS should record them without converting delivery-system or branding differences into unsupported efficacy rankings.
How this page differs from the longevity category
The broad longevity page answers: “What kinds of supplement approaches are currently sold around healthy ageing?” This page answers the narrower question: “How do current NAD-related formulas differ by precursor, dose and format?”
That boundary is important for retrieval. Users searching specifically for NAD, NR, nicotinamide riboside or related precursor comparisons should land on a page that does not spend most of its space discussing unrelated longevity products.
MenPS should also preserve uncertainty. If a current manufacturer page does not make the exact amount, serving or formulation sufficiently clear, the field should remain unverified rather than be filled from an old retailer page or inferred from the product name. That rule is especially important for time-sensitive supplement catalogs.
For example, two products can both use nicotinamide riboside while still presenting very different daily-use patterns. One may provide 300 mg in a single capsule, another may recommend two capsules for a 700 mg daily serving, and another may differentiate itself through a liposomal delivery system. Those are factual catalog differences that can be compared without making an efficacy judgment.
For NAD-focused products, the most useful normalized fields are precursor identity, chemical form where disclosed, amount per capsule or packet, manufacturer-recommended full serving, delivery format, number of active ingredients, and the date on which the label was checked. Brand name alone is not a sufficient comparison variable.
How an NAD product comparison should be normalized
An NAD precursor label is not a longevity claim
Official manufacturer pages are suitable for confirming product identity, ingredient form, amount per serving and current product positioning. Manufacturer claims about NAD-level changes or healthy ageing should be treated as manufacturer claims unless independently verified through the evidence layer. MenPS should not present the existence of an NR ingredient as proof that a product slows ageing or improves disease outcomes.
Current-source verification
Tru Niagen, Life Extension NAD+ Cell Regenerator, Renue By Science LIPO NR and DoNotAge Pure NR were freshly checked against current official manufacturer pages during this audit. Thorne NiaCel 400 remains a current Thorne healthy-ageing product, but its exact current amount is flagged for a final label check before any later material update.
Useful follow-up questions
Are all NAD supplements the same ingredient?
No. The current verified set here is heavily represented by nicotinamide riboside products, but NAD-support products can differ by precursor identity, dose and delivery format.
Is 300 mg the standard NR dose?
Several current products use 300 mg per capsule, but other products use different per-capsule or daily serving amounts. MenPS records the current label rather than defining one universal dose.
Does liposomal NR automatically work better?
No. Liposomal delivery is a product-format fact. It should not be treated as an efficacy conclusion without independent evidence.
Primary product sources used for this snapshot
Product identity, ingredient form, serving information and current commercial positioning were checked against official manufacturer pages. These sources support catalog facts, not independent efficacy conclusions.